• Madison Scientific

  Participated · Seed · Sep 2025

  MadSci (Madison Scientific) is developing the SmartShunt Hydrocephalus Management System, designed to integrate diagnostic and therapeutic functions for personalized hydrocephalus care. The SmartShunt System is a novel platform under development and is not yet authorized for use or available for sale in any country. Proceeds from the financing will accelerate product development, expand preclinical experience, and support team growth. Hydrocephalus affects at least one million children and adults in the U.S., and current treatments face high failure rates and diagnostic uncertainty, creating a significant unmet clinical need. Company leadership and investors cited strong confidence in MadSci’s technology and strategy to deliver improved solutions for patients and families. Madison Scientific is an early‑stage medical device company developing smart electro‑mechanical devices to improve treatment and long‑term care for patients with hydrocephalus and other neurologic conditions. Its lead product, the SmartShunt System, is designed to integrate diagnostic and therapeutic functions, and features a proprietary valve, an intracranial pressure (ICP) sensor, and advanced algorithms to optimize shunt drainage. The system aims to leverage ICP readings to reduce life‑threatening shunt failures and to enable on‑demand, personalized patient management. The SmartShunt is under development and is not yet authorized for use or available for sale in any country. Madison Scientific highlights the large addressable need — hydrocephalus affects roughly one million children and adults in the U.S. — and cites high failure rates for traditional shunts (nearly 40% within the first year).

• Arintra

  Participated · Series A · Aug 2025

  Arintra offers a GenAI-native platform that combines large language models with clinical knowledge graphs to interpret patient charts in context and apply specialty-specific coding guidelines. Every code the platform generates is fully explainable and auditable to build trust in high-stakes healthcare settings. The product integrates natively with Electronic Health Record systems including Epic and Athena and is designed to operate almost invisibly within existing clinical workflows. Leadership includes CEO Nitesh Shroff and CTO Preeti Bhargava. The company intends to use recent funding to accelerate product development and scale its team. Arintra also plans to open a new Bay Area headquarters to meet rising demand. Arintra builds a proprietary AI-driven platform that fully automates the majority of medical coding generation with no human intervention, using models built on top of open-source large language models. The product integrates without changing existing workflows for patients, clinicians, coders, or payers, enabling seamless deployment into hospital billing processes. Arintra’s models are trained on proprietary datasets and are designed to reduce claim denials, under-coding, and long receivable cycles, materially improving hospital revenue and cash flow. The founders, Nitesh and Preeti, hold PhDs (computer vision and computer science) from the University of Maryland and developed the platform over the past two years. The company targets a large, vertical market: US medical coding inefficiencies that the article estimates cost hospitals over $100 billion annually amid ~5 billion claims per year. Arintra builds an AI-powered assistant that automates clinical documentation and billing to help doctors save time and increase revenue. The product targets physician workflow by reducing administrative burden through automated documentation and billing processes. The team combines medical experts and AI specialists to develop the assistant. Arintra reports partnerships with 30+ healthcare organizations. The company states a mission to create the world’s most intelligent assistant for doctors and is positioning to scale that capability. It recently announced accelerator backing from Y Combinator.

• Lumeris

  Led · Equity · Apr 2024

  Lumeris operates as a value-based care managed services operator for health systems and providers, leveraging an AI-powered technology stack to collaborate with health systems and physician practices nationwide. It shares risk and operational responsibilities with providers to implement value-based models tailored to each population. Those models target Medicare Advantage, Traditional Medicare, Medicaid, and Commercial populations, aiming to improve quality metrics, enhance patient experience and physician satisfaction, and reduce total cost of care. The company is led by CEO Mike Long. Lumeris recently closed $100M in equity growth funding. It intends to use the funds to expand provider partnerships, including health systems and physician groups. Lumeris is a pioneer in population health management solutions. Through its operations, technology and consulting services, the company enables health care organizations to transition from volume- to value-based care. Its offerings help create Population Health Services Organizations, define populations for risk, and equip providers with process improvement strategies, technology tools, and clinical workflows. Lumeris also collaborates with payers to ensure appropriate contracts, measures and incentives are in place to influence physician behavior and drive quality, cost and utilization performance. A recent approximately $71 million private financing raised by its parent will be used to strengthen Lumeris’ market position and expand its value-based care solutions from eight to 20 U.S. markets. In its eight initial markets Lumeris has partnerships that provide services to 14 million consumers and expects to partner with organizations representing more than 50 million lives after the planned expansion. Essence Group (EGHC) operates through subsidiaries including Lumeris to deliver software, services and consulting for accountable health care. Lumeris supplies an integrated framework that delivers 22 core competencies through its Maestro, Maestro Plus and Tacklebox offerings. Maestro is described as an Enterprise Performance Management System that provides evidence-based decision support for payers, hospitals and physicians. The company says it built and tested its solutions for five years and measured results across hundreds of physicians and tens of thousands of patients. Most of the new capital from this financing will be invested in Lumeris to scale its accountable-care technologies and services. EGHC positions its offerings to help payers, hospitals and physician groups transition to value-driven, coordinated care.

No current team members are available.